Boca Raton,FL July 30, 2010 –THE STOCK WIZARDS FOCUS LISTS INCLUDES: (OTC: BLOKA ) Blockbuster, Inc. (OTCBB: GLER) Global Earth Energy, Inc. (OTCBB:APTD) AlphaTrade.com (NASDAQ: GERN) GERN — Geron Corp.
Learn to Trade Small Cap Penny Stocks from Expert Traders. Visit The TSW Website at http://www.TheStockWizards.net learn to make big profits.
Receive Our Hot OTC Newsletter Put out Every Weekend Highlighting Penny Stocks, Small Cap & Micro Cap Stocks before They Breakout. The Hottest weekend Newsletter Around.
+++++++++++++++++++++++
(OTC: BLOKA — Blockbuster, Inc.)
CURRENT NEWS!!
Clash of the Titans Available at BLOCKBUSTER: 28 Days Before Some Other Outlets
DALLAS, July 30, 2010 — Blockbuster Inc. (Pink Sheets: BLOKA) today announced availability of the movie, Clash of the Titans, in BLOCKBUSTER(R) stores and from BLOCKBUSTER By Mail a full four weeks before it will be available through some competitors. Blockbuster’s early advantage reflects its ongoing agreement with Warner Bros to provide customers with the opportunity to rent hit movies the day they are released on DVD. The movie will also be available from BLOCKBUSTER On Demand(R) on the release date.
“Blockbuster is thrilled to be able to give our customers immediate access to Clash of the Titans. Our four-week advance over key competitors reiterates to our customers that Blockbuster is a leading multichannel provider of home and mobile entertainment. This is possible because of our long-standing business relationships with the major studios including Warner Bros,” said James W. Keyes, chairman and chief executive officer, Blockbuster Inc.
Starring Sam Worthington, Liam Neeson, Ralph Fiennes, and directed by Louis Leterrie, Clash of the Titans brings Greek mythology to life with the ultimate battle between man and gods. Perseus, the mortal son of Zeus, fights to save his family from the dark god of the underworld, Hades. Perseus struggles to accept his power as a god, while he leads a mission to stop Hades before he can seize power from Zeus and unleash hell on earth.
“Our customers don’t have to wait weeks or years to see new releases. Clash of the Titans is the latest example of our ability to deliver fresh content that can be viewed anytime, anywhere. That means choice to access entertainment through a BLOCKBUSTER retail store, BLOCKBUSTER Express(R) kiosk, BLOCKBUSTER By Mail, or BLOCKBUSTER On Demand which provides movies over the internet directly to more than 80 models of Blu-ray Players, HDTVs, Blu-ray Home Theater Systems, DVRs and smart phones including T-Mobile’s HTC HD2 and Verizon’s Droid X,” said Keyes.
Blockbuster offers customers early availability of approximately 50 percent of the theatrical new releases as compared to key competitors including box office hits like Sherlock Holmes, Tooth Fairy, Valentine’s Day, and Invictus, and the highest grossing film of all-time, Avatar.
About Blockbuster Inc.
Blockbuster Inc. is a leading global provider of rental and retail movie and game entertainment. The company provides customers with convenient access to media entertainment anywhere, any way they want it – whether in-store, by-mail, through vending kiosks or digitally to their homes and mobile devices. With a highly recognized brand and a library of more than 125,000 movie and game titles, Blockbuster leverages its multichannel presence to serve nearly 47 million global customers annually. The company may be accessed worldwide at www.blockbuster.com.
Technical Outlook:
BLOKA Traders and Investors are watching for a weekly close above .20. A close above this level will spark some upside momentum. BLOKA is currently up 5.85% on volume of 635,862 shares in the morning session.
+++++++++++++++++++++++++++++
(OTCBB: GLER— Global Earth Energy, Inc.)
Current News !!
Global Earth Energy Doubles Capacity With Opening of New State-of-the-Art Facility
WILMINGTON, NC, Jul 30, 2010 — Global Earth Energy, Inc. (OTCBB: GLER) announced today that its wholly owned subsidiary RCI Solar, Inc., a North American provider of renewable energy products and services, has opened a new, 15,000 square foot, state-of-the-art facility that doubles its current capacity to serve customers throughout Ontario, Canada. The new facility houses all of the warehousing, distribution, inventory management and fulfillment functions.
“RCI Solar has made a strategic investment to ensure customer satisfaction at all three critical purchasing stages — distribution/logistics, dealer relationship management and customer service. Our new facility provides superior customer relations and product availability that is brand new to the area, adding to our competitive advantage,” said Syd Harland, CEO of Global Earth Energy, Inc.
“In addition to our new facility, we have upgraded our dealer relationship management services, including online utilities that foster a collaborative work environment and create new efficiencies along the supply chain. Our affiliates can easily exchange ideas, access video files and case studies, collect and retrieve product data and specification materials, as well as gain increased visibility across all customer touch points,” said Mel Dick, president of RCI Solar, Inc.
“With the price of customer acquisition at an all-time high, retaining customers and increasing the profitability of those relationships is critical. To best serve the end user, we also have deployed call center software that makes it easier to organize and integrate contact center activities with core business processes, and streamline them directly to the dealer network for local response and total customer satisfaction,” added Dick.
About Global Earth Energy, Inc.
Through its subsidiary RCI Solar, Inc., Global Earth Energy, Inc. provides renewable energy products and services to residential and commercial markets in North America. The Company sells complete turnkey renewable energy solutions based on three core products: Solar Domestic Hot Water, Solar Photo Voltaic (PV) Panels and AQUA III Heating & Cooling System. Along with these products, RCI Solar supplies a wide variety of fan convectors, solar storage tanks, controls, inverters, and ancillaries from its headquarters in Vancouver, British Columbia, Canada.
+++++++++++++++++++++++++++++
(OTCBB: APTD — AlphaTrade.com)
Current News !!
AlphaTrade Is Pleased to Announce “Operation Free-Gate”
PHOENIX, Jul 29, 2010 — AlphaTrade.com (OTCBB: APTD); It is with great enthusiasm that we are expanding and now offering “Operation Free-Gate.”
Operation Free-Gate is a collective effort of AlphaTrade management and several military personnel. The goal was to create an environment to educate individuals about the overall market, market conditions, as well as trading stocks, bonds, and options. Operation Free-Gate software also supports portfolio management, which is beneficial to the 23 million individuals that are serving in the military. It is AlphaTrade’s intention to launch “Operation Free-Gate” for not only active military personnel and Veterans in the United States and Canada but to everyone worldwide that could benefit from this service.
Gordon Muir, founder and CEO of AlphaTrade stated, “It is important to give back to those who unselfishly have defended our rights to freedom and a democratic way of life. AlphaTrade is not a large corporation with deep pockets, but we feel we need to do our part to help anyway we can.”
Muir goes on to state “We can help people understand economic health and learn market trends. It is our desire to educate them and give them the tools they need to set financial goals and build wealth for their future. Knowledge is the key to growth and success.”
AlphaTrade has a modified its fee schedule to entice new subscribers.
This news release and more information about AlphaTrade is available at www.alphatrade.com.
+++++++++++++++++++++++++++
(NASDAQ: GERN — GERN — Geron Corp.)
CURRENT NEWS!!
Geron to Proceed with First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
MENLO PARK, Calif., Jul 30, 2010 — Geron Corporation (Nasdaq:GERN) announced today that the U.S. Food and Drug Administration (FDA) has notified the company that the clinical hold placed on Geron’s Investigational New Drug (IND) application has been lifted and the company’s Phase I clinical trial of GRNOPC1 in patients with acute spinal cord injury may proceed.
The FDA notification enables Geron to move forward with the world’s first clinical trial of a human embryonic stem cell (hESC)-based therapy in man. The Phase I multi-center trial is designed to establish the safety of GRNOPC1 in patients with “complete” American Spinal Injury Association (ASIA) Impairment Scale grade A subacute thoracic spinal cord injuries.
“We are pleased with the FDA’s decision to allow our planned clinical trial of GRNOPC1 in spinal cord injury to proceed,” said Thomas B. Okarma, Ph.D., M.D., Geron’s president and CEO. “Our goals for the application of GRNOPC1 in subacute spinal cord injury are unchanged — to achieve restoration of spinal cord function by the injection of hESC-derived oligodendrocyte progenitor cells directly into the lesion site of the patient’s injured spinal cord. Additionally, we are now formally exploring the utility of GRNOPC1 in other degenerative CNS disorders including Alzheimer’s, multiple sclerosis and Canavan disease.”
The clinical hold was placed following results from a single preclinical animal study in which Geron observed a higher frequency of small cysts within the injury site in the spinal cord of animals injected with GRNOPC1 than had previously been noted in numerous foregoing studies. In response to those results, Geron developed new markers and assays as additional release specifications for GRNOPC1. The company completed an additional confirmatory preclinical animal study to test the new markers and assays, and subsequently submitted a request to the FDA for the clinical hold to be lifted.
GRNOPC1, Geron’s lead hESC-based therapeutic candidate, contains hESC-derived oligodendrocyte progenitor cells that have demonstrated remyelinating and nerve growth stimulating properties leading to restoration of function in animal models of acute spinal cord injury (Journal of Neuroscience, Vol. 25, 2005).
“The neurosurgical community is ready to begin the clinical testing of this new approach to treating devastating spinal cord injury,” said Richard Fessler, M.D., Ph.D., professor of neurological surgery at the Feinberg School of Medicine at Northwestern University. “We know that demyelination is central to the pathology of the injury, and its reversal by means of injecting oligodendrocyte progenitor cells would be revolutionary for the field. If found to be safe and effective, the therapy would provide a viable treatment option for thousands of patients who suffer severe spinal cord injuries each year.”
The GRNOPC1 Clinical Program
Patients eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury.
Although the primary endpoint of the trial is safety, the protocol includes secondary endpoints to assess efficacy, such as improved neuromuscular control or sensation in the trunk or lower extremities. Once safety in this patient population has been established, Geron plans to seek FDA approval to extend the study to increase the dose of GRNOPC1, enroll subjects with complete cervical injuries and expand the trial to include patients with severe incomplete (ASIA Impairment Scale grade B or C) injuries to enable access to the therapy for as broad a population of severe spinal cord-injured patients as is medically appropriate.
Geron has selected up to seven U.S. medical centers as candidates to participate in this study and in planned protocol extensions. The sites will be identified as they come online and are ready to enroll subjects into the study.
Other Potential Neurological Indications for GRNOPC1
In addition to spinal cord injury, GRNOPC1 may have therapeutic utility for other central nervous system indications. Geron has established a number of collaborations with academic groups to test GRNOPC1 in selected animal models of human disease for which there is a strong rationale for the approach.
Alzheimer’s Disease: Alzheimer’s disease is a progressive, fatal, degenerative disorder that attacks the neurons in the brain, resulting in loss of memory, cognitive function such as reasoning and language, and behavioral changes. According to the Alzheimer’s Association an estimated five million people in the United States have Alzheimer’s disease. GRNOPC1 is being evaluated in animal models of Alzheimer’s disease in collaboration with Professor Frank M. LaFerla, Director of the Institute for Memory Impairments and Neurological Disorders (UCI MIND) at the University of California, Irvine.
Multiple Sclerosis (MS): MS is an autoimmune disease that causes demyelination of nerve axons in the brain and spinal cord often progressing to physical and cognitive disability. There is currently no known cure for the disease. According to the National Multiple Sclerosis Society there are about 400,000 people in the United States with MS. GRNOPC1 is being tested in a non-human primate model of MS in collaboration with Professor Jeffery D. Kocsis of the Departments of Neurology and Neurobiology at Yale University School of Medicine and the Department of Veterans Affairs.
Canavan Disease: Canavan disease is a fatal neurological disorder that belongs to a group of genetic disorders called leukodystrophies, characterized by the abnormal development or degeneration of myelin. Symptoms of Canavan disease present in the first six months of life and death usually occurs at 3 — 10 years of age. GRNOPC1 is being tested in a rodent model of Canavan disease in collaboration with Dr. Paola Leone, Director of the Cell and Gene Therapy Center, at the University of Medicine and Dentistry of New Jersey.
Background on GRNOPC1
Additional information on Geron’s hESC programs and GRNOPC1 is available at Geron’s website www.geron.com.
About Geron
Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure and diabetes. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials in different cancers. For more information, visit www.geron.com.
+++++++++++++++++++++
About TheStockWizards.net
Please visit our website for Disclosures and Disclaimers and any conflicts of interest that there may be. http://thestockwizards.net/about/disclaimer/
Forward-Looking Statement: This press release includes “forward-looking statements” within the meaning of the federal securities laws, commonly identified by such terms as “believes,” “looking ahead,” “anticipates,” “estimates” and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company’s projections and expectations are disclosed in the Company’s filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.
TheStockWizards.net is not a registered investment advisers or broker/dealer.
TheStockWizards.net makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high risk.
Contact Info: E-mail: info@ thestockwizards.net
TheStockWizards.net 954-592-4770
